RBB

Daniel Gore

Dan Gore is a partner based in RBB’s London office with 20 years’ experience in competition economics consultancy. He is a co-author of The Economic Assessment of Mergers under European Competition Law (Cambridge University Press 2013, translated and republished by Law Press China 2017).

Dan has appeared in the Who’s Who Legal Future Leaders and Thought Leaders surveys of competition economists, which noted his “great depth of knowledge and strong grasp of the details” and “technical excellence” in merger analysis.

Dan’s practice focuses on merger assessment, and he has extensive experience in the analysis of horizontal, vertical and conglomerate mergers. He has also worked on numerous abuse of dominance cases, and investigations into concerted practices and information exchange.

Dan has worked on competition economics matters at the EU and European member state level, as well as assignments in the US, South Africa, Australia, Singapore and Malaysia. He has worked across a wide range of sectors, including grocery retailing, oil and gas (upstream and downstream), life sciences, IT, healthcare, broadcasting, telecoms and financial services. Clients include Shell, Booking, Euro Garages/ ASDA, Sony, Discovery Communications and Bupa.

Dan has published articles in the European Competition Law Review, and the Competition Law Journal. He holds a BSc in economics from University College London, and an MSc in economics from the University of Warwick.

Selected Cases

  • Booking/eTraveli

    Merger, EU

  • Euro Garages/ASDA

    Merger, UK

  • Thermo Fisher Scientific/Qiagen

    Merger, Global

  • Advent/DEM/HPM

    Merger, EU & Global

  • ASDA/Co-op stores

    Merger, UK

  • Sony Music Entertainment/AWAL

    Merger, UK

  • GE Healthcare

    Alleged abuse of dominance, Italy

  • Google/Looker

    Merger, UK

  • PIAM motor insurers’ association

    Alleged information exchange, Malaysia

A global network of experienced experts

Our 230-strong, multi-lingual team, spread across 16 offices, has managed over 3,000 cases in 120+ countries, advising on more than one-third of EU Phase II cases in the last 5 years.